Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

May 8, 2020

Study Completion Date

May 8, 2020

Conditions

Metastatic Solid Tumor CancerRecurrent Head and Neck Cancer

Interventions

DRUG

Ad-P53

Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine

DRUG

Xeloda

Oral metronomic chemotherapeutic agent

DRUG

Keytruda

Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors

DRUG

Opdivo

Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors

Trial Locations (1)

MD Anderson Cancer Center, Houston